Detalhe da pesquisa
1.
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
N Engl J Med;
388(19): 1739-1754, 2023 May 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37163621
2.
Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
Blood;
2024 Apr 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38620092
3.
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Blood;
142(11): 961-972, 2023 09 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37363867
4.
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Blood;
142(5): 446-459, 2023 08 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37172204
5.
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
Blood;
139(2): 177-187, 2022 01 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34758069
6.
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Blood;
139(9): 1318-1329, 2022 03 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35108374
7.
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.
Eur J Haematol;
2024 May 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38693677
8.
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Blood;
138(19): 1805-1816, 2021 11 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34086865
9.
Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group.
Ann Hematol;
102(11): 3083-3090, 2023 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37358640
10.
Long-term follow-up and health-related quality of life among cancer survivors with stage IEA orbital-type lymphoma after external photon-beam radiotherapy: Results from a longitudinal study.
Hematol Oncol;
40(5): 922-929, 2022 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35857866
11.
Early report on the severity of COVID-19 in hematologic patients infected with the SARS-CoV2 omicron variant.
Eur J Haematol;
109(4): 364-372, 2022 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35751531
12.
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.
Am J Hematol;
2024 May 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38757754
13.
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
Am J Hematol;
99(6): 1192-1195, 2024 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38578022
14.
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
Lancet Oncol;
19(9): 1215-1228, 2018 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30115596
15.
Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia.
Br J Haematol;
183(5): 727-735, 2018 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30460980
16.
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
Blood;
127(2): 208-15, 2016 Jan 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26486789
17.
CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.
Future Oncol;
14(6): 499-513, 2018 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29465308
18.
Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors.
Ann Rheum Dis;
80(12): e196, 2021 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31744827
19.
Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia.
Am J Hematol;
96(12): E457-E460, 2021 12 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34591989
20.
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.
Nat Med;
30(1): 240-248, 2024 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38071379